

# openheart Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis

Chun Shing Kwok,<sup>1</sup> Sunil V Rao,<sup>2</sup> Phyo K Myint,<sup>3</sup> Bernard Keavney,<sup>1</sup> James Nolan,<sup>4</sup> Peter F Ludman,<sup>5</sup> Mark A de Belder,<sup>6</sup> Yoon K Loke,<sup>7</sup> Mamas A Mamas<sup>1</sup>

**To cite:** Kwok CS, Rao SV, Myint PK, *et al*. Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis. *Open Heart* 2014;**1**:e000021. doi:10.1136/openhrt-2013-000021

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/openhrt-2013-000021>).

Received 13 December 2013  
Revised 11 January 2014  
Accepted 18 January 2014



CrossMark

For numbered affiliations see end of article.

**Correspondence to**  
Dr Mamas A Mamas;  
[mamasmamas1@yahoo.co.uk](mailto:mamasmamas1@yahoo.co.uk)

## ABSTRACT

**Objectives:** To examine the relationship between periprocedural bleeding complications and major adverse cardiovascular events (MACEs) and mortality outcomes following percutaneous coronary intervention (PCI) and study differences in the prognostic impact of different bleeding definitions. **Methods:** We conducted a systematic review and meta-analysis of PCI studies that evaluated periprocedural bleeding complications and their impact on MACEs and mortality outcomes. A systematic search of MEDLINE and EMBASE was conducted to identify relevant studies. Data from relevant studies were extracted and random effects meta-analysis was used to estimate the risk of adverse outcomes with periprocedural bleeding. Statistical heterogeneity was assessed by considering the  $I^2$  statistic.

**Results:** 42 relevant studies were identified including 533 333 patients. Meta-analysis demonstrated that periprocedural major bleeding complications was independently associated with increased risk of mortality (OR 3.31 (2.86 to 3.82),  $I^2=80%$ ) and MACEs (OR 3.89 (3.26 to 4.64),  $I^2=42%$ ). A differential impact of major bleeding as defined by different bleeding definitions on mortality outcomes was observed, in which the REPLACE-2 (OR 6.69, 95% CI 2.26 to 19.81), STEEPLE (OR 6.59, 95% CI 3.89 to 11.16) and BARC (OR 5.40, 95% CI 1.74 to 16.74) had the worst prognostic impacts while HORIZONS-AMI (OR 1.51, 95% CI 1.11 to 2.05) had the least impact on mortality outcomes.

**Conclusions:** Major bleeding after PCI is independently associated with a threefold increase in mortality and MACEs outcomes. Different contemporary bleeding definitions have differential impacts on mortality outcomes, with 1.5–6.7-fold increases in mortality observed depending on the definition of major bleeding used.

## INTRODUCTION

Advances in antithrombotic therapy have improved the outcomes of patients undergoing

## KEY MESSAGES

- The strength of this systematic review was the large number of studies included with over half a million total participants.
- Another strength was that we were able to evaluate the effect of different major bleeding definitions and its impact on risk of mortality and major adverse cardiovascular events.
- This systematic review had the limitation that studies included varied in antithrombotic and antiplatelet regimes after PCI procedure.
- Another limitation was that the systematic review was unable to evaluate whether the subsequent mortality was directly related to the bleed.

percutaneous coronary intervention (PCI) through the reduction of ischaemic events at the expense of increased procedure-related bleeding complications. Major bleeding events in contemporary PCI are significant, with 30-day bleeding event rates reported between 0.7% and 1.1% in elective,<sup>1–3</sup> 0.6% and 4.7%<sup>3–6</sup> in non-ST-elevation myocardial infarction (NSTEMI) and 0.9% and 8.9% in ST-elevation myocardial infarction (STEMI)<sup>3 4 7 8</sup> depending on the definition used.

There are currently around 10 different definitions of major bleeding used in trials and registries of patients undergoing PCI<sup>9 10</sup> and these definitions include various clinical events, such as blood transfusion or retroperitoneal haemorrhage, laboratory parameters, such as differing values of haemoglobin decreases, and clinical outcomes such as mortality<sup>9</sup> resulting in significant differences in bleeding event recording across clinical trials thereby making comparisons between therapeutic strategies difficult. Furthermore, the incidence of major bleeding varies depending on definition used. In

one study, the RIVAL non-coronary artery bypass graft (non-CABG) related major bleeding occurred in 0.87% in the STEMI cohort and 0.57% in the NSTEMI group, while if an ACUITY major bleeding definition was used, major bleeding occurred in 3.1% in the STEMI group and 2.26% in the NSTEMI group, respectively.

Major periprocedural bleeding complications following PCI are predictors of mortality and major adverse cardiovascular events (MACEs),<sup>11–13</sup> with up to 12.1% of all in-hospital mortality after PCI in the National Cardiovascular Data Registry's CathPCI Registry related to bleeding complications.<sup>14</sup> In contrast, other studies have suggested that although bleeding may be causally related to adverse outcomes in some patients in the real-world setting, it is often merely a marker for patients at higher risk for adverse outcomes.<sup>15 16</sup>

Some prior studies that have reported on the prognostic impact of major bleeds have not accounted for differences in baseline covariates such as age, syndrome of presentation and comorbidities that would themselves impact on MACEs and mortality outcomes.<sup>17–21</sup> In contrast, while other studies have adjusted for baseline covariates, different definitions of major bleeding such as TIMI,<sup>2 11 22 23</sup> GUSTO,<sup>20 24</sup> STEEPLE<sup>20 25</sup> and BARC<sup>23</sup> have been used, which have been shown to have differential impacts on mortality/MACEs outcomes.<sup>20 23 26</sup> Furthermore, the timing of bleeding from index PCI procedures included in such studies has varied from 48 h,<sup>25</sup> been limited to those that occur in hospital,<sup>23 27</sup> to 30 days<sup>2 28</sup> with impact on mortality and MACEs outcomes studied at different time points such as 30 days,<sup>8 24 28</sup> 6 months<sup>24 27</sup> or 1 year.<sup>2 22 23 25</sup>

Until today, there has not been a systematic review or meta-analysis previously published studying the prognostic impact of periprocedural major bleeding events on mortality and MACEs outcomes following PCI. We have therefore undertaken a meta-analysis to systematically study the impact of major bleeding following PCI on mortality and MACEs outcomes. In this meta-analysis, we provide an overview of the cohorts evaluating the rates of major bleeding events and systematically study the differences in the prognostic impact of different bleeding definitions and the relationship between major bleeding and clinical events at different time points.

## METHODS

### Eligibility criteria

We selected studies of patients who underwent PCI that reported on mortality or cardiovascular events among patients with and without major bleeding events. There was no restriction based on study design, definition of major bleeding or the indication for PCI or its status as an urgent or elective procedure. We excluded studies that did not report on categories of major bleeding and those that did not report either mortality or MACEs.

### Search strategy

A search of EMBASE (1974 to January 2014) and MEDLINE (1946 to January 2014) was conducted on OvidSP. The search terms are shown in online supplementary figure S1. We did not use any language restrictions. We checked the bibliographies of included studies and relevant review articles found on the search for additional relevant articles.

### Study selection and data extraction

Two reviewers (CSK and YKL) checked all titles and abstracts for studies that could potentially meet the inclusion criteria. We retrieved full reports of these potentially eligible studies and independently extracted data on study design, participant characteristics, interventions used, major bleeding events, follow-up, outcome events and methods of ascertaining measured clinical events on to a preformatted spreadsheet. Any discrepancies between the two reviewers were resolved by consensus after consulting a third reviewer (MAM).

### Quality assessment

Risk of bias was assessed by considering four different areas: ascertainment of major bleeding events, ascertainment of outcome events, extent of loss to follow-up and the use of adjustment for confounders in the analysis. We also assess for publication bias using funnel plots when there were >10 studies available in the meta-analysis and there was no evidence of substantial statistical heterogeneity.<sup>29</sup>

### Data analysis

We used RevMan V.5.1.7 (Nordic Cochrane Centre) to do random effects meta-analysis using the inverse variance methods for pooled ORs. We assumed similarity between the OR and other relative measures such as relative risk, rate ratios or HRs because cardiovascular events and death were rare events.<sup>30</sup> The analysis was stratified based on whether the results had considered the effect of potential confounders through adjustments or propensity-matched cohorts or not. In order to reduce the risk of bias from confounding so that we have a more reliable estimate of the independent effect of bleeding on prognosis, we appraised studies with multivariate adjustments or propensity-matched cohorts separately from studies with crude or unadjusted results. We used adjusted or propensity-matched risk estimates where available. For datasets reporting multiple time points, we took the earliest time point for the primary analysis. Any later time points were subsequently analysed in the separate Forest plots stratified according to timing of outcome assessment. Where there were multiple definitions of major bleeding we choose to use the results for TIMI major bleeding.

We planned for three analyses. The primary analysis was the pooled adjusted and unadjusted risk of mortality with and without major bleed. The secondary analysis

was the unadjusted and adjusted risk of MACEs with and without major bleed. In a post hoc sensitivity analysis, we conducted a pooled analysis after excluding studies where it was clear that only some (and not all) of the participants had undergone PCI.

### Statistical heterogeneity

We used the  $I^2$  statistic to assess statistical heterogeneity.  $I^2$  Values of 30–60% represent moderate levels of heterogeneity.<sup>31</sup>

## RESULTS

### Study selection

The process of selection of studies is shown in online supplementary figure S1. We retrieved 42 relevant studies of patients that underwent PCI (total number of participants 533 333), which evaluated the risk of adverse events with and without major bleeding.<sup>2 8 11 14 17–23 27 28 32–58</sup> The number of participants in each study ranged from 352 to 280 390 and the number of major bleeding events was 66 277 (37 studies, 15.3%). A total of 40 studies evaluated mortality as an outcome and 11 studies reported on MACEs.

### Description of studies included

The study designs, date of study, country of origin and indication for PCI is shown in [table 1](#). There were 12 studies (149 650 participants), which were post hoc analyses of randomised controlled trials and 1 matched observational study (280 390 participants). Of the studies that reported number of centres, there were more multicentre studies than single centre studies (n=17 and n=13). The age and gender of participants along with the antiplatelet and anticoagulant regimes used is shown in online supplementary table S1.

[Table 2](#) shows the timing of major bleeding, definition of major bleeding used in the individual studies and the incidence of major bleeding in each study. While many of the studies did not report when assessment for major bleeding took place (n=15), 15 of the studies clearly stated that they evaluated in-hospital major bleeding. The definitions of major bleeding also varied among the included studies and formal definitions of major bleeding included TIMI, GUSTO, STEEPLE, HORIZON-AMI, CRUSADE, BARC and REPLACE-2 definitions. These definitions are summarised in online supplementary table S2. Follow-up of patients in the studies included in this analysis varied from 48 h to more than 3 years. The impact of major bleeding on clinical outcomes was adjusted for baseline covariates in 22 studies (490 699 participants) while in 20 studies (42 634 participants) only unadjusted outcomes were reported.

### Quality assessment

Online supplementary table S3 shows the quality assessment for included studies. Ascertainment of bleeding

and mortality varied from data collection from medical record reviews to prospective evaluation in trials where independent committees adjudicated bleeding and outcome events.

### Major bleeding and risk of mortality at any time point

The impact of major bleeding on mortality outcomes was studied in 40 studies reporting outcomes in 525 691 patients. In total, 66 016 major bleeds were reported. Crude rates or risk estimates for mortality in individual studies are shown in online supplementary table S4. Mortality rate was 3595/62 036 (5.8%, 28 studies) in patients who sustained a major bleed and 8937/370 522 (2.4%, 28 studies) in patients not experiencing major bleeding complications.

Meta-analysis of these data demonstrated that the overall risk of mortality was significantly greater among patients who sustained major bleeding complications periprocedurally ([figure 1](#)). The risk estimate for mortality was significantly lower in the subgroup of studies, which adjusted for potential confounders (OR 3.31 (2.86 to 3.82),  $I^2=80%$ , 491 565 participants compared to the OR calculated in those studies that did not adjust for baseline covariates; OR 6.75 (4.99 to 9.12),  $I^2=62%$ , 34 126 participants).

### Major bleeding and risk of MACEs at any time point

The impact of major bleeding on MACEs outcomes was studied in 13 studies reporting outcomes in 69 843 patients. Crude rates or risk estimates for MACEs in individual studies are shown in [tables 3](#) and [4](#); 757 major bleeds (6.8%) were reported.

MACE rates were 295/1701 (17.3%) in patients who sustained a major bleed and 2101/38 520 (5.4%) in patients not experiencing major bleeding complications. The overall risk of MACEs was significantly higher among patients with major bleeds ([figure 2](#)). The risk of MACEs did not significantly differ in the subgroup of studies that adjusted for baseline covariates (OR 3.89 (3.26 to 4.64),  $I^2=42%$ , 25 829 participants as compared to those that did not adjust for baseline covariates OR 3.12 (2.32 to 4.19),  $I^2=52%$ , 101 184 participants).

### Mortality with major bleeding at different follow-up durations

The adjusted risk of mortality was significantly greater among patients with major bleeds at all time points evaluated ([figure 3](#)). For 30-day mortality, adjusted risk was OR 3.24 (2.73 to 3.84,  $I^2=81%$ , 11 studies, 403 457 participants) and at 6 months, the OR remained elevated at 3.23 (2.92 to 3.57,  $I^2=0%$ , 4 studies, 50 872 participants; [table 3](#)). At the 1-year time point, the risk of mortality was OR 3.64 (2.39 to 5.56,  $I^2=89%$ , 9 studies).

### MACEs with bleeding at different follow-up durations

Analysis of the impact of major bleeding on MACEs outcomes at different time points was stratified into risk of

**Table 1** Study design, year of study, country of origin and participant inclusion criteria

Study ID	Design	Date of study	Number of centres	Country	Inclusion criteria
Amlani <i>et al</i> <sup>32</sup>	Prospective cohort	May 2003 to July 2007	Single centre	Canada	Patients with STEMI
Ariza-Sole <i>et al</i> <sup>33</sup>	Prospective cohort	October 2009 to April 2012	Single centre	Spain	Patients with STEMI
Barthélémy <i>et al</i> <sup>20</sup>	Prospective cohort	NA	Single centre	France	Patients in E-Paris Registry with STEMI and PCI
Bertrand <i>et al</i> <sup>34</sup>	Post hoc analysis of RCT	October 2003 to April 2005	Single centre	Canada	Patients in EASY trial with PCI without STEMI
Boden <i>et al</i> <sup>35</sup>	Cohort	NA	NA	The Netherlands	Patients with STEMI and PCI
Budaj <i>et al</i> <sup>36</sup>	Post hoc analysis of RCT	NA	Multicentre	International	Patients with NSTEMI ACS. Note that only 64–79% had PCI
Cayla <i>et al</i> <sup>18</sup>	Post hoc analysis of RCT	NA	Multicentre	France	Patients in ABOARD trial with NSTEMI and PCI
Cayla <i>et al</i> <sup>37</sup>	Post hoc analysis of RCT	NA	Multicentre	International	Patients in ATOLL study with STEMI and PCI
Chhatriwalla <i>et al</i> <sup>14</sup>	Matched cohort	2004 to 2011	Multicentre	USA	Patients in the CathPCI Registry
Correia <i>et al</i> <sup>38</sup>	Cohort	August 2007 to December 2010	Multicentre	Brazil	Patients with ACS. Note that only 76–90% had coronary angiogram
Eikelboom <i>et al</i> <sup>28</sup>	Post hoc analysis of RCTs	NA	Multicentre	International	Patients in OASIS 1 and 2 and CURE who had ACS. Note that only 10–11% had PCI/stent/atherectomy
Fuchs <i>et al</i> <sup>21</sup>	Prospective cohort	January 2001 to June 2005	Single centre	Israel	Patients with STEMI and PCI
Gitt <i>et al</i> <sup>39</sup>	Cohort	October 2006 to October 2008	Multicentre	International	Patients with ACS. Note that only 65–82% had primary/rescue PCI
Giugliano <i>et al</i> <sup>8</sup>	Post hoc analysis of RCT	NA	Multicentre	International	Patients in EXTRACT-TIMI 25 trial where patients received fibrinolysis
Hermanides <i>et al</i> <sup>22</sup>	Prospective cohort	January 1991 to December 2004	Single centre	The Netherlands	Patients with STEMI and PCI
Kaul <i>et al</i> <sup>40</sup>	Post hoc analysis of RCT	May 2004 to August 2008	Multicentre	International	Patients with NSTEMI
Kikkert <i>et al</i> <sup>41</sup>	Prospective cohort	January 2003 to July 2008	Single centre	The Netherlands	Patients with STEMI and PCI
Kinnaird <i>et al</i> <sup>11</sup>	Retrospective cohort	1991 to 2000	NA	USA	Patients who underwent PCI
Le May <i>et al</i> <sup>42</sup>	Cohort	May 2005 to July 2010	NA	Canada	Patients with STEMI and PCI
Lee <i>et al</i> <sup>43</sup>	Prospective cohort	February 2003 to March 2006	NA	Korea	Patients with PCI with DES
Lemesle <i>et al</i> <sup>27</sup>	Cohort	January 2000 to December 2007	Single centre	USA	Patients ≥80 years of age with PCI
Lindsey <i>et al</i> <sup>44</sup>	Prospective cohort	July 2004 to January 2006	Multicentre	USA	Patients in EVENT registry with PCI
Lopes <i>et al</i> <sup>45</sup>	Retrospective cohort	November 2001 to December 2006	Multicentre	USA	Patients in CRUSADES registry and subset with PCI

Continued



**Table 1** Continued

Study ID	Design	Date of study	Number of centres	Country	Inclusion criteria
Matic <i>et al</i> <sup>46</sup>	Cohort	August 2009 to December 2012	NA	Serbia	Patients with STEMI and PCI
Matic <i>et al</i> <sup>47</sup>	Cohort	August 2009 to December 2010	NA	Serbia	Patients with STEMI and PCI
Matic <i>et al</i> <sup>48</sup>	Prospective cohort	August 2009 to December 2010	NA	Serbia	Patients with STEMI and PCI
Mehran <i>et al</i> <sup>2</sup>	Post hoc analysis of RCTs	NA	Multicentre	International	Patients in REPLACE-2, ACUITY and HORIZONS-AMI trial with PCI
Montalescot <i>et al</i> <sup>25</sup>	Post hoc analysis of RCT	December 2005 to December 2006	Multicentre	International	Patients in STEEPLE trial who underwent elective PCI
Mrdovic <i>et al</i> <sup>49</sup>	Cohort	February 2006 to December 2009	Single centre	Serbia	Patients with STEMI and PCI
Musumeci <i>et al</i> <sup>50</sup>	Cohort	June 2005 to June 2008	Multicentre	Italy	Patients with PCI and DES
Ndrepepa <i>et al</i> <sup>17</sup>	Post hoc analysis of RCT	September 2005 to January 2008	NA	Germany	Patients in ISAR-REACT-3 trial with PCI
Ndrepepa <i>et al</i> <sup>23</sup>	Post hoc analysis of RCT	NA	NA	Germany	Patients in ISAR-REACT, ISAR-SWEET, ISAR-SMART and ISAR-REACT-2 trials with PCI
Pierre-Louis <i>et al</i> <sup>51</sup>	Cohort	NA	NA	USA	Patients with ACS and PCI
Pilgrim and Wenaweser <sup>52</sup>	Cohort	May 2002 to December 2005	Single centre	Switzerland	Patients with PCI
Polanska-Skrzypczyk <i>et al</i> <sup>53</sup>	Prospective cohort	February 2001 to October 2002	Single centre	Poland	Patients with STEMI and PCI
Poludasu <i>et al</i> <sup>54</sup>	Prospective cohort	July 2001 to May 2010	Multicentre	USA	Patient with PCI
Rao <i>et al</i> <sup>24</sup>	Post hoc analysis of RCTs	NA	Multicentre	International	Patients in GUSTO IIb, PURSUIT and PARAGON A/B. Note that only 11–30% had PCI
Rossini <i>et al</i> <sup>55</sup>	Cohort	NA	NA	USA	Patients with PCI and DES
Urban <i>et al</i> <sup>56</sup>	Prospective cohort	May 2006 to April 2008	Multicentre	International	Patients in e-SELECT registry with PCI and DES
Valente <i>et al</i> <sup>19</sup>	Prospective cohort	January 2004 to December 2008	Single centre	Italy	Patients in Intensive Cardiac Care Florence STEMI Registry who had STEMI and PCI
Yoon <i>et al</i> <sup>57</sup>	Cohort	NA	NA	Korea	Patients in IRS DES registry with PCI and DES
Zheng <i>et al</i> <sup>58</sup>	Retrospective cohort	January 2004 to January 2008	Single centre	China	Patients with elective or urgent PCI

ACS, acute coronary syndromes; DES, drug-eluting stent; NA, not applicable; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; RCT, randomised controlled trial; STEMI, ST-elevation myocardial infarction.

**Table 2** Timing of bleeding, definition of major bleeding and follow-up


Study ID	Timing of bleeding	Major/severe bleeding criteria	Number of participants in bleeding group	Number of participants in control group	Follow-up
Amlani <i>et al</i> <sup>32</sup>	Within 30 days	Haemoglobin drop $\geq 5$ g/dL, intracranial haemorrhage, bleeding requiring surgery or blood transfusion of at least 2 units	152 (67 had PCI)	1237 (566 had PCI)	30 days
Ariza-Sole <i>et al</i> <sup>33</sup>	In-hospital	CRUSADE	33	1031	Mean follow-up 344 days
Barthélémey <i>et al</i> <sup>20</sup>	In-hospital	TIMI, GUSTO, STEEPLE	Total 671	NA	1 year
Bertrand <i>et al</i> <sup>34</sup>	Unclear	REPLACE-2	19	1329	30 days, 6 months, 1 year
Boden <i>et al</i> <sup>35</sup>	In-hospital	CRUSADE	203	762	1 year
Budaj <i>et al</i> <sup>36</sup>	Up to 180 days	ESSENCE	771 (30 days), 937 (180 days)	18 851 (30 days), 18 851 (180 days)	180 days
Cayla <i>et al</i> <sup>18</sup>	30 days	STEEPLE	19	333	30 days
Cayla <i>et al</i> <sup>37</sup>	30 days	STEEPLE	42	868	30 days
Chhatriwalla <i>et al</i> <sup>14</sup>	In-hospital	CathPCI Registry definition	56 078	224 312	In-hospital
Correia <i>et al</i> <sup>38</sup>	In-hospital	BARC type 3 or 5	29	426	In-hospital
Eikelboom <i>et al</i> <sup>28</sup>	Within 30 days	Bleeding that was significantly disabling, bleeding requiring transfusion of $\geq 2$ units of packed cells or bleeding that was life threatening	783	3363	30-day mortality
Fuchs <i>et al</i> <sup>21</sup>	Unclear	TIMI	27	804	30 days and 6 months
Gitt <i>et al</i> <sup>39</sup>	In-hospital	Drop in haemoglobin of $>5$ g/dL or haematocrit of $>15\%$	281	8451	In-hospital
Giugliano <i>et al</i> <sup>8</sup>	Up to day 8	TIMI	309	20 014	30 days
Hermanides <i>et al</i> <sup>22</sup>	48 h	TIMI	80	4371	30 days and 1 year
Kaul <i>et al</i> <sup>40</sup>	Up to 120 h after randomisation	GUSTO	598	8808	30 days
Kikkert <i>et al</i> <sup>41</sup>	Unclear	TIMI	35	331	1–30 days
Kinnaird <i>et al</i> <sup>11</sup>	Unclear	TIMI	588	8992	In-hospital
Le May <i>et al</i> <sup>42</sup>	Unclear	TIMI	91	1941	6 months
Lee <i>et al</i> <sup>43</sup>	Median 1366 days	STEEPLE	148	3022	Median 1366 days
Lemesle <i>et al</i> <sup>27</sup>	In-hospital	Decrease in haematocrit of $\geq 15\%$ and/or the occurrence of a major haematoma/gastrointestinal bleeding/intracerebral bleeding	127	2639	6 months
Lindsey <i>et al</i> <sup>44</sup>	In-hospital	TIMI	180	5781	1 year
Lopes <i>et al</i> <sup>45</sup>	In-hospital	CRUSADE	3902	28 993	30 days, 1 year, 3 year, $>3$ years
Matic <i>et al</i> <sup>46</sup>	Unclear	GUSTO	32	738	In-hospital
Matic <i>et al</i> <sup>47</sup>	Unclear	HORIZONS-AMI	88	1154	30 day

Continued

**Table 2** Continued

Study ID	Timing of bleeding	Major/severe bleeding criteria	Number of participants in bleeding group	Number of participants in control group	Follow-up
Matic <i>et al</i> <sup>48</sup>	Unclear	BARC	114	1558	1 year
Mehran <i>et al</i> <sup>2</sup>	30 days	TIMI	267	17 034	Up to 1 year
Montalescot <i>et al</i> <sup>25</sup>	48 h	STEEPLE	3528 (total)	NA	1 year
Mrdovic <i>et al</i> <sup>49</sup>	Unclear	TIMI	22	2074	30 days and 1 year
Musumeci <i>et al</i> <sup>50</sup>	30 days, 12 months, any follow-up	TIMI	52	1385	3 years
Ndrepepa <i>et al</i> <sup>17</sup>	Unclear	REPLACE-2	555	4015	1 year
Ndrepepa <i>et al</i> <sup>23</sup>	In-hospital	TIMI, REPLACE-2, BARC	Total 12 459	NA	30 days, 1 year
Pierre-Louis <i>et al</i> <sup>51</sup>	In-hospital	Intracerebral or intraocular bleeding, clinical bleeding requiring blood transfusion, clinical bleeding with a reduction in haematocrit >10 points, retroperitoneal or gastrointestinal bleeding, access site bleeding requiring intervention, and ≥4 cm diameter vascular access site haematoma	34	600	In-hospital
Pilgrim and Wenaweser <sup>52</sup>	In-hospital	TIMI	48	3787	30 days
Polanska-Skrzypczyk <i>et al</i> <sup>53</sup>	In-hospital	TIMI	40	1024	1 year
Poludasu <i>et al</i> <sup>54</sup>	Unclear	HORIZONS-AMI	396	11 595	2.3 years
Rao <i>et al</i> <sup>24</sup>	Unclear	GUSTO	2908	23 544	Up to 6 months
Rossini <i>et al</i> <sup>55</sup>	Unclear	TIMI	57	1301	1 year
Urban <i>et al</i> <sup>56</sup>	Unclear	STEEPLE	Total 15 147	NA	360 days
Valente <i>et al</i> <sup>19</sup>	In-hospital	TIMI, ACUITY	Total 991	NA	In-ICCU
Yoon <i>et al</i> <sup>57</sup>	In-hospital	BARC type 2–5	234	5932	2 years
Zheng <i>et al</i> <sup>58</sup>	Unclear	TIMI	27	385	1 year

ICCU, intensive coronary care unit; NA, not applicable; PCI, percutaneous coronary intervention.



**Figure 1** Adjusted risk of mortality with and without major bleed after percutaneous coronary intervention.

MACE <1 year and  $\geq 1$  year due to the limited number of studies presenting MACE data and its relationship with time. The adjusted risk of MACE <1 year was OR 3.96 (3.26 to 4.81,  $I^2=53\%$ , 2 studies, 47 422 participants) and for  $\geq 1$  year was OR 3.19 (1.89 to 5.37, 1 study, 3170 participants; [table 3](#)).

Adverse outcomes and different definitions for major bleeding

The impact of different definitions of major bleeding on mortality and MACEs outcomes are presented in [table 4](#). REPLACE-2 (OR 6.69 (2.26 to 19.81),  $I^2=84\%$ , 3 studies, 17 996 participants) definition of major bleeding had

**Table 3** Summary of risk of mortality and MACEs among patients with and without major bleed after percutaneous coronary intervention at different time points

Duration	OR	I <sup>2</sup> (%)	Number of participants	Number of events in bleed group/total	Number of events in non-bleed group/total
<b>Adjusted risk of mortality</b>					
30 days <sup>8 14 24 28 32 36 38 39 40 41 45</sup>	3.24 (2.73 to 3.84)	81	403 457	3307/59 630	7645/317 375
6 months <sup>24 27 36 42</sup>	3.23 (2.92 to 3.57)	0	50 872	154/1028	1119/20 606
1 year <sup>2 22 23 25 44 48 53 56</sup>	3.64 (2.39 to 5.56)	89	74 637	160/2494	677/36 167
<b>Adjusted risk of MACEs</b>					
<1 year <sup>24 34 36</sup>	3.96 (3.26 to 4.81)	53	47 422	175/790	1204/20 180
>1 year <sup>43</sup>	3.19 (1.89 to 5.38)	NA	3170	NA	NA

MACEs, major adverse cardiovascular events; NA, not applicable.



**Table 4** Summary of risk of mortality and MACEs among patients with and without major bleed after percutaneous coronary intervention with different definitions of bleeding

Mortality				MACEs			
Definition of major bleed	OR	I <sup>2</sup> (%)	Number of participants	Definition	OR	I <sup>2</sup>	Number of participants
BARC <sup>23 38 48</sup>	5.40 (1.74 to 16.74)	88	14 550	BARC	NA	NA	NA
CRUSADE <sup>33 35 45</sup>	3.69 (1.68 to 8.12)	85	14 055	CRUSADE	NA	NA	NA
GUSTO <sup>24 40 46</sup>	4.30 (3.76 to 4.92)	0	27 222	GUSTO <sup>24</sup>	4.37 (3.78 to 5.07)	NA	26 452
HORIZON-AMI <sup>47 54</sup>	1.51 (1.11 to 2.05)	12	13 233	HORIZON-AMI	NA	NA	NA
REPLACE <sup>17 23 34</sup>	6.69 (2.26 to 19.81)	84	17 996	REPLACE	NA	NA	NA
STEEPLE <sup>18 25 37 43 56</sup>	6.59 (3.89 to 11.16)	53	23 107	STEEPLE <sup>43</sup>	3.19 (1.89 to 5.37)	NA	3170
TIMI <sup>2 8 11 19 20 21 22 42 44 49 50 52 53 55</sup>	5.15 (4.01 to 6.61)	69	69 449	TIMI <sup>21</sup>	2.41 (1.42 to 4.35)	NA	1348
Other <sup>14 27 28 32 36 39 51</sup>	3.34 (2.59 to 4.32)	76	346 670	Other <sup>36</sup>	3.99 (3.3 to 4.82)	NA	19 622

MACEs, major adverse cardiovascular events; NA, not applicable.

the greatest impact on mortality outcomes, while the ACUTY/HORIZONS-AMI had the least impact (OR 1.51 (1.11 to 2.05), I<sup>2</sup>=12%, 1 study, 13 233 participants).

### Sensitivity analysis


Sensitivity analysis excluding studies where not all participants had PCI did not significantly alter the pooled analysis for association between major bleeding and mortality (OR 3.16 (2.61 to 3.81), I<sup>2</sup>=75%, 372 449 participants).


## DISCUSSION

Advances in antithrombotic and antiplatelet therapy have improved outcomes following PCI through the reduction of ischaemic events although this has been at the expense of increased procedure-related bleeding complications. Our meta-analysis of 42 studies including

over half a million patients confirms that major bleeding is independently associated with a threefold increase in mortality and MACEs outcomes, and that this increased mortality and MACEs risk observed following a major bleed is sustained for periods of over 1 year. We also show that major bleeding events as defined by different contemporary bleeding definitions have differential impacts on mortality outcomes, with 1.5–6.7-fold increases in mortality observed depending on the definition of major bleeding used.

There are a number of potential mechanisms that may underlie the relationship between major bleeding and adverse mortality outcomes. Patients that sustain major bleeding complications post PCI are more likely to be older, have renal failure, undergo PCI for STEMI/NSTEMI presentations, present with haemodynamic compromise or have a history of heart failure<sup>2 59</sup> that also

**Figure 2** Adjusted risk of major adverse cardiovascular event with and without major bleed after percutaneous coronary intervention.



**Figure 3** Risk of mortality with major bleed with different duration of follow-up.

independently predict adverse mortality outcomes themselves. Many previous studies<sup>17–21</sup> that have reported on the prognostic impact of major bleeds have not accounted for differences in such baseline covariates that are themselves known to impact on mortality outcomes, which would overestimate the mortality risks associated with a major bleed. For example, in an analysis from the Global Registry of Acute Coronary Events (GRACE), major bleeding was no longer associated with 6-month mortality after adjustment for the known comorbidities with the authors concluding that comorbidities associated with major bleeding accounting for the higher rate of mortality in patients who bled.<sup>15</sup> Consistent with this, we have observed that in meta-analysis of studies that do not adjust for baseline covariates, major bleeding is associated with a sixfold increased risk in mortality, but this decreases to a threefold independent increase in mortality once baseline covariates are adjusted for, suggesting that major bleeding is independently linked to mortality and MACEs outcomes.

The potential mechanisms by which a major bleed adversely impacts on clinical outcomes are numerous. Major bleeds such as an intracranial haemorrhage or severe blood loss as can occur in a gastrointestinal haemorrhage may result in mortality directly, although such bleeding events would not explain the persistent mortality risk observed for over a year following a major bleeding event in our meta-analysis. Major bleeds may necessitate the discontinuation of antiplatelet or antithrombotic medications that increase the risk for stent thrombosis, a strong independent predictor of mortality outcomes in the short and longer term (>1 year).<sup>60</sup> Furthermore, increased production of erythropoietin in response to anaemia that occurs following a major bleed may contribute to a prothrombotic systemic state beyond the acute phase through platelet activation and induction of plasminogen activator inhibitor-1 (PAI-1).<sup>61–62</sup> Treatment with erythropoietin has been associated with increased risk of thrombosis in critical care patients<sup>63</sup> and increase in the composite endpoint of death, acute myocardial infarction, stroke and stent thrombosis in patients with STEMI.<sup>64</sup> Blood transfusions have been

linked to adverse shorter and longer term mortality<sup>65</sup> and have been shown to predict 30-day mortality<sup>66</sup> independently of bleeding and haematocrit. Adverse mortality outcomes associated with blood transfusions occur through a number of mechanisms including prothrombotic effects mediated through acute platelet release of CD40 ligand,<sup>67</sup> platelet activation and induction of PAI-1<sup>61</sup> an inhibitor of endogenous fibrinolytic mechanisms. These increased risks of mortality also extend to non-red blood cell transfusions such as platelets or plasma/cryoprecipitate that may also be utilised following a periprocedural major bleed.<sup>68</sup>

Our observations of a differential impact of different major bleeding definitions on mortality outcomes is particularly pertinent suggesting that the choice of bleeding definition used has significantly influenced the outcome of previous studies, since the definition employed will influence the prevalence of reported bleeds as well as their prognostic impact. For example, in the RIVAL study<sup>69</sup> non-CABG related major bleeding as defined by the study was not significantly different between the radial and femoral arms of the study (OR=0.73, 95% CI 0.43 to 1.23; p=0.9), while use of the ACUTY major bleeding criterion was associated with a statistically significant reduction in major bleeding in the radial arm of the study (OR=0.43, 95% CI 0.32 to 0.57; p<00001). Similarly, in the SYNERGY trial that used the GUSTO and TIMI major definition of bleeding, the enoxaparin arm was associated with a significantly higher rate of major bleeding as defined by TIMI major criteria but no difference in major bleeding as defined by the GUSTO major definition. Definitions that encompass less severe bleeding events (such as the ACUTY definition) are not as strongly linked to adverse events and therefore may not be a powerful means of evaluating bleeding avoidance strategies. In order to prove efficacy for bleeding avoidance the use of a more discriminative definition would be preferable.

Our meta-analysis has a number of potential limitations. First, an inherent limitation of any meta-analysis is that of publication bias; studies that show a neutral outcome in mortality are less likely to be published than those that show a positive outcome and thus tend to bias any meta-analysis of published data towards a more positive outcome. Second, studies included in this meta-analysis often used different antithrombotic and antiplatelet regimes for the PCI procedures undertaken for different indications, hence it is unclear whether the prognostic impact of a major bleed differs with different antiplatelet/anticoagulant combinations or whether it differs in the elective/acute coronary syndrome setting. Finally, our current analysis does not provide insight into whether the timing of the major bleed in relation to the index PCI procedure has a differential impact on mortality outcomes.

In conclusion, our meta-analysis of 42 studies including over half a million patients has revealed that major bleeding is independently associated with a threefold

increase in mortality and MACEs outcomes, and that this increased mortality and MACEs risk observed following a major bleed is observed for periods of over 1 year. We also show that major bleeding events as defined by different contemporary bleeding definitions have differential impacts on mortality outcomes. Given the significant impact of major bleeding on mortality outcomes, formal bleeding risk assessment should be undertaken as part of the decision-making process for PCI procedures and bleeding avoidance strategies such as optimal pharmacotherapy and access site choice should be actively undertaken, particularly in those patients at highest baseline risk for bleeding complications.

#### Author affiliations

<sup>1</sup>Cardiovascular Institute, University of Manchester, Manchester, UK

<sup>2</sup>Department of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA

<sup>3</sup>Division of Applied Health Sciences, School of Medicine & Dentistry, University of Aberdeen, Aberdeen, Scotland, UK

<sup>4</sup>Department of Cardiology, University Hospital North Staffordshire, Stoke-on-Trent, UK

<sup>5</sup>Department of Cardiology, Queen Elizabeth Hospital, Birmingham, UK

<sup>6</sup>Cardiothoracic Division, The James Cook University Hospital, Middlesbrough, UK

<sup>7</sup>Norwich Medical School, University of East Anglia, Norwich, UK

**Contributors** CSK, MAM and YKL contributed to planning, conduct and reporting of the work. SVR, PKM, BK, JN, PFL and MDB contributed to the interpretation of the findings and reporting of the work. MAM is the guarantor and was responsible for the overall content.

**Competing interests** None.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

#### REFERENCES

1. Lincoff AM, Kleiman NS, Kereiakes DJ, *et al.* Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. *JAMA* 2004;292:696–703.
2. Mehran R, Pocock S, Nikolsky E, *et al.* Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomas to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. *JACC Cardiovasc Interv* 2011;4:654–64.
3. Subherwal S, Peterson ED, Dai D, *et al.* Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry. *J Am Coll Cardiol* 2012;59:1861–9.
4. Mehta SR, Jolly SS, Cairns, *et al.* RIVAL Investigators. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. *J Am Coll Cardiol* 2012;60:2490–9.
5. Mehran R, Pocock SJ, Stone GW, *et al.* Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. *Eur Heart J* 2009;30:1457–66.
6. Happe LE, Rao SV, Horblyuk R, *et al.* Consequences of major bleeding in hospitalized patients with non-ST segment elevation acute coronary syndromes receiving injectable anticoagulants. *Curr Med Res Opin* 2009;25:413–20.
7. Stone GW, Witzenschnitzer B, Guagliumi G, *et al.* Bivalirudin during primary PCI in acute myocardial infarction. *N Engl J Med* 2008;358:2218–30.
8. Giugliano RP, Giraldez RR, Morrow DA, *et al.* Relationship between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. *Eur Heart J* 2010;31:2103–10.
9. Rao SV, Mehran R. Evaluating the bite of the BARC. *Circulation* 2012;125:1344–6.
10. Mehran R, Rao SV, Bhatt DL, *et al.* Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. *Circulation* 2011;123:2736–47.
11. Kinnaird TD, Stabile E, Mintz GS, *et al.* Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. *Am J Cardiol* 2003;92:930–5.
12. Manoukian SV, Feit F, Mehran R, *et al.* Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY trial. *J Am Coll Cardiol* 2007;49:1362–8.
13. Rao SV, Eikelboom JA, Granger CB, *et al.* Bleeding and blood transfusion issues inpatients with non-ST-segment elevation acute coronary syndromes. *Eur Heart J* 2007;28:1193e204.
14. Chhatiwalla AK, Amin AP, Kennedy KF, *et al.* Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. *JAMA* 2013;309:1022–9.
15. Spencer FA, Moscucci M, Granger CB, *et al.* Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? *Circulation* 2007;116:2793–801.
16. Berger PB, Manoukian SV. Bleeding is bad...isn't it? *Circulation* 2007;116:2776–8.
17. Ndrepepa G, Schulz S, Keta D, *et al.* Bleeding after percutaneous coronary intervention with bivalirudin or unfractionated heparin and one-year mortality. *Am J Cardiol* 2010;105:163–7.
18. Cayla G, Silvain J, Barthelemy O, *et al.* Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. *Heart* 2011;97:887–91.
19. Valente S, Lazzari C, Chiofalo M, *et al.* STEMI patients—the more you bleed, the more you die: a comparison between classifications. *Clin Cardiol* 2011;34:90–6.
20. Barthélémy O, Silvain J, Brieger D, *et al.* Bleeding complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction in a radial center. *Catheter Cardiovasc Interv* 2012;79:104–12.
21. Fuchs S, Kornowski R, Teplinsky I, *et al.* Major bleeding complicating contemporary primary percutaneous coronary interventions—incidence, predictors, and prognostic implications. *Cardiovasc Revasc Med* 2009;10:88–93.
22. Hermanides RS, Ottervanger JP, Dambrink JH, *et al.* Incidence, predictors and prognostic importance of bleeding after primary PCI for ST-elevation myocardial infarction. *EuroIntervention* 2010;6:106–11.
23. Ndrepepa G, Schuster T, Hadamitzky M, *et al.* Validation of the bleeding academic research consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. *Circulation* 2012;125:1424–31.
24. Rao SV, O'Grady K, Pieper KS, *et al.* Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. *Am J Cardiol* 2005;96:1200–6.
25. Montalescot G, Gallo R, White HD, *et al.* Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. *JACC Cardiovasc Interv* 2009;2:1083–91.
26. Rao SV, O'Grady K, Pieper KS, *et al.* A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. *J Am Coll Cardiol* 2006;47:809–16.
27. Lemesle G, Labriolle AD, Bonello L, *et al.* Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention. *Cather Cardiovasc Interv* 2009;74:428–35.
28. Eikelboom JW, Mehta SR, Anand SS, *et al.* Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. *Circulation* 2006;114:774–82.



29. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry test for publication bias in meta-analyses: a large survey. *CMAJ* 2007;176:1091–6.
30. Davies HT, Crombie IK, Tavakoli M. When odds ratios mislead? *BMJ* 1998;316:989–91.
31. Deeks JJ, Higgins JP, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. *Cochrane handbook for systematic reviews of interventions*. John Wiley & Sons, 2008. [http://handbook.cochrane.org/chapter\\_9/9\\_5\\_2\\_identifying\\_and\\_measuring\\_heterogeneity.htm](http://handbook.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm)
32. Amlani S, Nadarajah T, Afzal R, et al. Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. *J Thromb Thrombolysis* 2010;30:434–40.
33. Ariza-Sole A, Sanchez-Elvira G, Sanchez-Salado JC, et al. CRUSADE bleeding risk score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Thromb Res* 2013;132:652–8.
34. Bertrand OF, Larose E, Rodés-Cabau J, et al. Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy. *Am Heart J* 2009;157:164–9.
35. Boden H, Velders M, van der Hoeven, et al. The risk of in-hospital bleeding and long-term mortality in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. *J Am Coll Cardiol* 2012;60:B161–2.
36. Budaj A, Wikelboom JW, Mehta SR, et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndrome. *Eur Heart J* 2009;30:655–1.
37. Cayla G, Barthelemy O, Silvain J, et al. Anticoagulation, arterial access and bleeding in primary PCI: an analysis of the randomized ATOLL trial. *Eur Heart J* 2012;33:462.
38. Correia LC, Sabino M, Brito M, et al. Causality analysis of the relationship between bleeding and lethality in acute coronary syndrome. *Arq Bras Cardiol* 2012;98:488–96.
39. Gitt AK, Bauer T, Hochadel MG, et al. Impact of radial arterial access for PCI in acute coronary syndromes on bleeding complications in clinical practice: results of the Euro Heart Survey PCI-registry. *Eur Heart J* 2010;31(Suppl 1):659.
40. Kaul P, Tanguay JF, Newby LK, et al. Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the early versus delayed, provisional Eptifibatid in Acute Coronary Syndromes (EARLY ACS) trial. *Am Heart J* 2013;166:723–8.
41. Kikkert WJ, Zwinderman AH, Vis MM, et al. Timing of mortality after severe bleeding and recurrent myocardial infarction in patients with ST-segment-elevation myocardial infarction. *Circ Cardiovasc Interv* 2013;6:391–8.
42. Le May M, MacDougall A, So D, et al. Impact of bleeding on mortality in patients referred for primary PCI in ST-elevation myocardial infarction. *Can J Cardiol* 27(5 Suppl 1):S219.
43. Lee JY, Kim YH, Kim WJ, et al. Long-term clinical impact of bleeding after percutaneous coronary intervention with drug-eluting stent in real world practice. *J Am Coll Cardiol* 2009;53:A45.
44. Lindsey JB, Marso SP, Pencina M, et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients. Results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. *JACC Cardiovasc Interv* 2009;2:1074–82.
45. Lopes RD, Subherwal S, Holmes DN, et al. The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST segment myocardial infarction. *Eur Heart J* 2012;33:2044–53.
46. Matic D, Mrdovic I, Stankovic G, et al. Incidence, predictors and prognostic implications of bleeding complicating contemporary primary percutaneous coronary interventions. *Eur Heart J* 2010;31(Suppl 1):5.
47. Matic D, Stankovic G, Antonijevic N, et al. Prognostic implications of bleeding complicating STEMI treated with primary percutaneous coronary intervention. *Eur Heart J* 2011;32(Suppl 1):394.
48. Matic D, Milasinovic D, Asanin M, et al. Prognostic implications of bleeding measured by Bleeding Academic Research Consortium (BARC) categorization in patients treated with primary percutaneous coronary intervention. *Eur Heart J* 2012;33(Suppl 1):208–9.
49. Mrdovic I, Savic L, Asanin M, et al. Sex-related analysis of short- and long-term clinical outcomes and bleeding among patients treated with primary percutaneous coronary intervention: an evaluation of the RISK-PCI data. *Can J Cardiol* 2013;29:1097–103.
50. Musumeci G, Rossini R, Lettieri C, et al. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. *Catheter Cardiovasc Interv* 2012;80:395–405.
51. Pierre-Louis B, Aronow WS, Yoon JH, et al. Risk factors for major bleeding and for minor bleeding after percutaneous coronary intervention in 634 consecutive patients with acute coronary syndromes. *Am J Ther* 2010;17:e74–7.
52. Pilgrim TM, Wenaweser P. Impact of bleeding on clinical outcome in patients undergoing PCI. *Eur H J* 2010;31(Suppl 1):658.
53. Polanska-Skrzypczyk M, Karcz M, Bekta P, et al. Major bleeding is a predictor of mid-term mortality in STEMI patients treated with primary PCI. The ANIN myocardial infarction registry. *Eur Heart J* 2011;32(Suppl 1):876–7.
54. Poludasu S, Baber U, Clark AE, et al. Impact of major bleeding on long term mortality in patients with and without anemia undergoing percutaneous coronary intervention with bivalirudin. *TCT Abstracts JACC* 2011;58(20 Suppl B):B17.
55. Rossini R, Musumeci G, Lettieri C, et al. Long-term bleeding events in patients with prolonged dual antiplatelet therapy after DES implantation. *Eur Heart J* 2010;31(Suppl 1):167.
56. Urban P, Abizaid A, Banning A, et al. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. *J Am Coll Cardiol* 2011;57:1445–54.
57. Yoon YH, Kim YH, Park KM, et al. Impact of in-hospital bleeding on major adverse cardiac events and stroke using bleeding academic research consortium classification in patients who undergoing percutaneous coronary intervention. *Am J Cardiol* 2013;111(Suppl 7):91B.
58. Zheng HC, Q Zhang Q, Zhang RY, et al. Clinical outcomes of patients with major bleeding after primary coronary intervention for acute ST-segment elevation myocardial infarction. *J Interv Radiol* 2009;18:808–11.
59. Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. *Circ Cardiovasc Interv* 2009;2:222–9.
60. Dangas GD, Claessen BE, Mehran R, et al. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. *J Am Coll Cardiol* 2012;59:1752–9.
61. Doyle BJ, Rihal CS, Gastineau DA, et al. Bleeding blood transfusion and increased mortality after percutaneous coronary intervention. *J Am Coll Cardiol* 2009;53:2019–27.
62. Smith KJ, Bleyer AJ, Little WC, et al. The cardiovascular effects of erythropoietin. *Cardiovasc Res* 2003;59:538–48.
63. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. *N Engl J Med* 2007;357:965–76.
64. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. *JAMA* 2011;305:1863–72.
65. Chase AJ, Fretz EB, Warburton WP, et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R. T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). *Heart* 2008;94:1019–25.
66. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. *JAMA* 2004;292:1555–62.
67. Yacoub D, Hachem A, Théorêt JF, et al. Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. *Arterioscler Thromb Vasc Biol* 2010;30:2424–33.
68. Robinson SD, Janssen C, Fretz EB, et al. Non-red blood cell transfusion as a risk factor for mortality following percutaneous coronary intervention. *Int J Cardiol* 2012;157:169–73.
69. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. *Lancet* 2011;377:1409–20.

# Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis

Chun Shing Kwok, Sunil V Rao, Phyo K Myint, Bernard Keavney, James Nolan, Peter F Ludman, Mark A de Belder, Yoon K Loke and Mamas A Mamas

*Open Heart* 2014 1:  
doi: 10.1136/openhrt-2013-000021

---

Updated information and services can be found at:  
<http://openheart.bmj.com/content/1/1/e000021>

---

*These include:*

- |                               |  |
|-------------------------------|--|
| <b>Supplementary Material</b> | Supplementary material can be found at:<br><a href="http://openheart.bmj.com/content/suppl/2014/02/14/1.1.e000021.DC1.html">http://openheart.bmj.com/content/suppl/2014/02/14/1.1.e000021.DC1.html</a>   |
| <b>References</b>             | This article cites 58 articles, 18 of which you can access for free at:<br><a href="http://openheart.bmj.com/content/1/1/e000021#BIBL">http://openheart.bmj.com/content/1/1/e000021#BIBL</a>   |
| <b>Open Access</b>            | This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <a href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</a> |
| <b>Email alerting service</b> | Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.   |
- 

## Notes

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>